Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Migraine
NEJM 377:553-561, Charles, A., 2017
Acute Headache Diagnosis in Pregnant Women
Neurol 85:1024-1030, Robbins, M.S.,et al, 2015
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Intravenous Dihydroergotamine for Inpatient Management of Refractory Primary Headaches
Neurol 77:1827-1832, Nagy, A.J.,et al, 2011
Headache in Transplant Patients
www.medlink.com, Aug, Lai, T.H., 2011
Status Epilepticus Migrainosus: Clinical, Electrophysiologic, and Imaging Characteristics
Neurol 75:373-374, Perucca,P., et al, 2010
Hemorrhagic Manifestations of Reversible Cerebral Vasoconstriction Syndrome: Frequency, Features, and Risk Factors
Stroke 41:2505-2511, 2455, Ducros,A.,et al, 2010
The Emergency Management of Headaches
The Neurologist 9:93-98, Green,M.W., 2003
Idiopathic Stabbing Headache Associated With Monocular Visual Loss
Arch Neurol 57:745-746, Ammache,Z.,et al, 2000
Acetazolamide Treatment for Migraine Aura Status
Neurol 55:1588-1589, Haan,J.,et al, 2000
Safety and Efficacy of Ergotamine Tartrate & Dihydroergotamine in the Trmt of Migraine & Status Migrainosus
Neurol 45:577-584, Silberstein,S.D.,et al, 1995
Practice Parameter:Appropriate Use of Ergotamine Tartrate & Dihydroergotamine in the Trmt of Migraine & Status Migrainosus
Neurol 45:585-587, , 1995
The Transient Syndrome of Headache with Neurologic Deficits and CSF Lymphocytosis
Neurol 45:1648-1654, Berg,M.J.&Williams,L.S., 1995
Diagnosing the Severe Headache
Neurol 44:S6-S12, Dalessio,D.J., 1994
Validity of Family History Data on Severe Headache and Migraine
Neurol 43:1954-1960, Ottman,R.,et al, 1993
Symptomatic and Prophylactic Treatment of Migraine and Tension-Type Headache
Neurol 42:16-21, Schulman,E.A.&Silberstein,S.D., 1992
Idiopathic Intracranial Hypertension Without Papilledema
Arch Neurol 48:392-399, Marcelis,J.&Silberstein,S.D., 1991
Randomized Double-Blind Trial of Intravenous Prochlorperazine for the Treatment of Acute Headache
JAMA 261:1174-1176, Jones,J.,et al, 1989
Possible Benefit of GR43175, A Novel 5-HT1-Like Receptor Agonist for the Acute Treatment of Severe Migraine
Lancet 1:1309-1311, Doenicke,A.,et al, 1988
Repetitive Intravenous Dihydroergotamine as Therapy for Intractable Migraine
Neurol 36:995-997, Raskin,N.H., 1986
Icepick-like Pain
Neurol 30:203-205, Raskin,N.H.&Schwartz,R.K., 1980
Genetic Causes of Cerebral Small Vessel Diseases, A Parctical Guide for Neurologists
Neurol 100:766-783, Manini,A.,&Pantoni,L., 2023
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Migraine, hearing loss, and blurred vision in a young woman
Neurol 95:e2945-e2950, Sasikumar, S.,et al, 2020
Factors Associated with Risk of Recurrent Transient Global Amnesia
JAMA Neurol 77:1551-1558, Morris, K.A.,et al, 2020
Cyclic Vomiting Syndrome in Children
AJGH 2:doi:10.33552/AJGH.2020, Al-Ansari, N., 2020
Encephalopathy in a Large Cohort of British Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Patients
Stroke 50:283-290, Drazyk, A.M.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Vestibular Migraine
BMJ 366:L4213, Li, V.,et al, 2019
Treatment Effects and Comorbid Diseases in 58 Patients with Visual Snow
Neurol 93:e398-e403, vanDongen, R.M.,et al, 2019
Acute Treatment of Migraine in Children and Adolescents
Neurol 93:487-499, Oskoui, M.,et al, 2019
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Acute Vestibular Migraine Treatment with Noninvasive Vagus Nerve Stimulation
Neurol 93:e1715-e1719, Beh, S.C. & Friedman, D.I., 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Abdominal Migraine
BMJ 360;k179, Angus-Leppan, H.,et al, 2018
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018